U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07448116) titled 'Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.' on Jan. 31.
Brief Summary: This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the anti-EGFR/c-Met bispecific antibody MCLA-129 in combination with Ensartinib hydrochloride in patients with advanced solid tumors.
Study Start Date: Jan. 31
Study Type: INTERVENTIONAL
Condition:
Solid Advanced Tumor
Intervention:
DRUG: MCLA-129
MCLA-129 is a bispecific antibody that targets both EGFR and c-Met, simultaneously blocking the signaling pathways of both EGFR and c-Me...